



Balfour Capital Group Boston Scientific Corporation

Boston Scientific is a global medical technology company that develops, manufactures, and markets minimally invasive medical devices. Its products are used in various interventional medical specialties, including cardiology, electrophysiology, endoscopy, urology, gynecology, and neuromodulation. The company's mission is to transform lives through innovative medical solutions that improve patient health worldwide.

1. Top 5 Competitors

Boston Scientific's primary competitors in the medical device industry include:

- Medtronic
- Abbott Laboratories
- Johnson & Johnson
- Stryker Corporation
- Becton, Dickinson and Company (BD)

2. Largest Institutional Shareholders

As of the latest data, major institutional shareholders of Boston Scientific include:

- PRIMECAP Management Co. – 2.50% ownership
- BlackRock Life Ltd. – 2.47%
- Wellington Trust Co., NA – 2.45%
- Geode Capital Management LLC – 2.08%
- Capital Research & Management Co. (World Investors) – 1.89%

Overall, institutional investors own approximately 89.07% of the company's stock.

3. Management Team:

Key executives at Boston Scientific include:

- Michael F. Mahoney – Chairman and Chief Executive Officer
- Daniel J. Brennan – Executive Vice President and Chief Financial Officer



Balfour Capital Group Boston Scientific Corporation

4. Revenue

For the fiscal year ending December 31, 2024, Boston Scientific reported net sales of \$16.747 billion, representing a 17.61% increase from the previous year.

5. Institutions with Buy Recommendations:

Several financial institutions have issued positive recommendations for Boston Scientific, including:

- Raymond James
- Wells Fargo
- Citigroup
- Morgan Stanley

These firms have maintained strong buy ratings and have raised their price targets for the stock.

6. Summary of Analyst Sentiment:

Analyst sentiment toward Boston Scientific is overwhelmingly positive. The company has an average brokerage recommendation (ABR) of 1.18 on a scale where 1.0 indicates a Strong Buy. Additionally, out of 28 analysts, 25 have issued Strong Buy ratings, and 2 have issued Buy ratings.

7. Insider Buying and Selling Over the Last 24 Months:

Over the past 24 months, Boston Scientific insiders have sold a total of 1,265,993 shares, amounting to approximately \$87.38 million. In the last 6 months, there has been 1 purchase and 30 sales by insiders.